Key Insights

Highlights

Treatment Research

5 treatments under study, led by Ren001

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

80.0%

4 terminated out of 5 trials

Success Rate

20.0%

-66.6% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

400%

4 of 1 completed with results

Key Signals

4 with results

Data Visualizations

Phase Distribution

5Total
Phase 1 (1)
Phase 2 (2)
Phase 2/3 (1)
Phase 3 (1)

Trial Status

Terminated4
Completed1

Trial Success Rate

20.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT04641962Phase 2TerminatedPrimary

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

NCT05267574Phase 2/3TerminatedPrimary

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

NCT04535609Phase 2CompletedPrimary

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

NCT03323749Phase 3TerminatedPrimary

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

NCT03862846Phase 1TerminatedPrimary

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Showing all 5 trials

Research Network

Common Treatments

  • Ren0012
  • Mavodelpar1
  • Elamipretide Open Label Treatment1
  • Bocidelpar1
  • Elamipretide1

Active Sponsors

  • Reneo Pharma Ltd3
  • Astellas Pharma Inc1
  • Stealth BioTherapeutics Inc.1

Top Investigators

Activity Timeline